You are here
Clinical Trials: Cord Blood
Condition: Haematologic Disease
Intervention: Combination Product: CTL 19
Sponsors: Nantes University Hospital; INSERM U01232 CRCINA
Not yet recruiting
Intervention: Combination Product: CTL 19
Sponsors: Nantes University Hospital; INSERM U01232 CRCINA
Not yet recruiting
Conditions: Safety Issues; Efficiency
Intervention: Biological: microtransplantation
Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Not yet recruiting
Intervention: Biological: microtransplantation
Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Not yet recruiting
Conditions: High Risk Hematological Malignancy; Cord Blood Transplant
Intervention: Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Sponsors: ExCellThera inc.; Fred Hutchinson Cancer Research Center
Recruiting
Intervention: Biological: ECT-001-CB (UM171-Expanded Cord Blood Transplant)
Sponsors: ExCellThera inc.; Fred Hutchinson Cancer Research Center
Recruiting
Condition: Cerebral Palsy
Interventions: Biological: Low HLA group CBU infusion; Biological: High HLA group CBU infusion; Other: Standard therapy
Sponsors: State-Financed Health Facility "Samara Regional Medical Center Dinasty"; INBIO, LLC
Recruiting
Interventions: Biological: Low HLA group CBU infusion; Biological: High HLA group CBU infusion; Other: Standard therapy
Sponsors: State-Financed Health Facility "Samara Regional Medical Center Dinasty"; INBIO, LLC
Recruiting
Conditions: Acute Erythroid Leukemia; Acute Lymphoblastic Leukemia; Acute Megakaryoblastic Leukemia; Acute Myeloid Leukemia; Blasts Under 10 Percent of Bone Marrow Nucleated Cells; Blasts Under 5 Percent of Bone Marrow Nucleated Cells; Chronic Myelogenous Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphoid Cell Neoplasm; Human Immunodeficiency Virus Positive; Myelodysplastic Syndrome; Myelodysplastic Syndrome With Excess Blasts; Non-Hodgkin Lymphoma; Refractory Anemia
Interventions: Drug: Fludarabine; Drug: Fludarabine Phosphate; Drug: Cyclophosphamide; Drug: Thiotepa; Radiation: Total-Body Irradiation; Procedure: Umbilical Cord Blood Transplantation; Other: Cellular Therapy
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
Interventions: Drug: Fludarabine; Drug: Fludarabine Phosphate; Drug: Cyclophosphamide; Drug: Thiotepa; Radiation: Total-Body Irradiation; Procedure: Umbilical Cord Blood Transplantation; Other: Cellular Therapy
Sponsors: Fred Hutchinson Cancer Research Center; National Cancer Institute (NCI); National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting
Condition: Pulmonary Hypertension
Interventions: Biological: adipose derived mesenchymal stem cells; Drug: Conventional drug therapy（expectorant，bronchodilator）
Sponsor: Liaocheng People's Hospital
Recruiting
Interventions: Biological: adipose derived mesenchymal stem cells; Drug: Conventional drug therapy（expectorant，bronchodilator）
Sponsor: Liaocheng People's Hospital
Recruiting
Condition: Irreversible Pulpitis
Interventions: Other: Cord blood stem cells; Other: Saline solution
Sponsor: University of California, San Francisco
Not yet recruiting
Interventions: Other: Cord blood stem cells; Other: Saline solution
Sponsor: University of California, San Francisco
Not yet recruiting
Condition: Knee Osteoarthritis
Interventions: Biological: SMUP-IA-01(low-dose); Biological: SMUP-IA-01(mid-dose); Biological: SMUP-IA-01(high-dose)
Sponsor: Medipost Co Ltd.
Not yet recruiting
Interventions: Biological: SMUP-IA-01(low-dose); Biological: SMUP-IA-01(mid-dose); Biological: SMUP-IA-01(high-dose)
Sponsor: Medipost Co Ltd.
Not yet recruiting
Condition: Viral Infection
Intervention: Biological: HLA-matched VSTs
Sponsors: Baylor College of Medicine; The Methodist Hospital System; Texas Children's Hospital
Not yet recruiting
Intervention: Biological: HLA-matched VSTs
Sponsors: Baylor College of Medicine; The Methodist Hospital System; Texas Children's Hospital
Not yet recruiting
Conditions: Stroke; Umbilical Cord Blood; Erythropoietin; Safety; Treatment Outcome
Interventions: Drug: Umbilical cord blood infusion; Drug: Erythropoietin injection; Drug: Placebo umbilical cord blood infusion; Drug: Placebo erythropoietin injection; Procedure: Active rehabilitation
Sponsors: Bundang CHA Hospital; Korea Evaluation Institute of Industrial Technology
Recruiting
Interventions: Drug: Umbilical cord blood infusion; Drug: Erythropoietin injection; Drug: Placebo umbilical cord blood infusion; Drug: Placebo erythropoietin injection; Procedure: Active rehabilitation
Sponsors: Bundang CHA Hospital; Korea Evaluation Institute of Industrial Technology
Recruiting
